Photo from wikipedia
Key Points Blinatumomab was associated with low incidence of grade 3 or 4 cytokine release syndrome (n = 2; 1.8%) and neurologic events (n = 4; 3.6%). The best blinatumomab… Click to show full abstract
Key Points Blinatumomab was associated with low incidence of grade 3 or 4 cytokine release syndrome (n = 2; 1.8%) and neurologic events (n = 4; 3.6%). The best blinatumomab outcomes were seen in patients achieving CR with no MRD who received alloHSCT, independent of genetic abnormalities.
Keywords:
blinatumomab pediatric;
refractory cell;
cell acute;
pediatric relapsed;
relapsed refractory;
acute lymphoblastic
Journal Title: Blood Advances
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Blood Advances
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!